Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal antibody targeting PD-L1 within the PD-1/PD-L1 pathway. Demonstrating significant antitumor activity, this antibody is particularly effective in treating solid tumors, such as extensive-stage small-cell lung cancer (SCLC). Adebrelimab's mechanism of action involves modulating the immune response by inhibiting the PD-1/PD-L1 interaction, thereby enhancing the body's antitumor immune activity. This product is pivotal for research focused on immune checkpoint pathways and cancer immunotherapy.
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal antibody targeting PD-L1 within the PD-1/PD-L1 pathway. Demonstrating significant antitumor activity, this antibody is particularly effective in treating solid tumors, such as extensive-stage small-cell lung cancer (SCLC). Adebrelimab's mechanism of action involves modulating the immune response by inhibiting the PD-1/PD-L1 interaction, thereby enhancing the body's antitumor immune activity. This product is pivotal for research focused on immune checkpoint pathways and cancer immunotherapy.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
